Cover Image

Lung cancer mortality reduction by LDCT screening: results from the randomized German LUSI trial

In 2011, the U.S. National Lung Cancer Screening Trial (NLST) reported a 20% reduction of lung cancer mortality after regular screening by low-dose computed tomography (LDCT), as compared to X-ray screening. The introduction of lung cancer screening programs in Europe awaits confirmation of these fi...

Full description

Saved in:
Bibliographic Details
Main Authors: Becker, Nikolaus (Author) , Motsch, Erna (Author) , Trotter, Anke (Author) , Heußel, Claus Peter (Author) , Dienemann, Hendrik (Author) , Schnabel, Philipp Albert (Author) , Kauczor, Hans-Ulrich (Author) , González Maldonado, Sandra (Author) , Miller, Anthony B. (Author) , Kaaks, Rudolf (Author) , Delorme, Stefan (Author)
Format: Article (Journal)
Language:English
Published: 2020
In: International journal of cancer
Year: 2019, Volume: 146, Issue: 6, Pages: 1503-1513
ISSN:1097-0215
DOI:10.1002/ijc.32486
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/ijc.32486
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.32486
Get full text
Author Notes:Nikolaus Becker, Erna Motsch, Anke Trotter, Claus P. Heussel, Hendrik Dienemann, Philipp A. Schnabel, Hans-Ulrich Kauczor, Sandra González Maldonado, Anthony B. Miller, Rudolf Kaaks and Stefan Delorme
Description
Summary:In 2011, the U.S. National Lung Cancer Screening Trial (NLST) reported a 20% reduction of lung cancer mortality after regular screening by low-dose computed tomography (LDCT), as compared to X-ray screening. The introduction of lung cancer screening programs in Europe awaits confirmation of these first findings from European trials that started in parallel with the NLST. The German Lung cancer Screening Intervention (LUSI) is a randomized trial among 4,052 long-term smokers, 50-69 years of age, recruited from the general population, comparing five annual rounds of LDCT screening (screening arm; n = 2,029 participants) with a control arm (n = 2,023) followed by annual postal questionnaire inquiries. Data on lung cancer incidence and mortality and vital status were collected from hospitals or office-based physicians, cancer registries, population registers and health offices. Over an average observation time of 8.8 years after randomization, the hazard ratio for lung cancer mortality was 0.74 (95% CI: 0.46-1.19; p = 0.21) among men and women combined. Modeling by sex, however showed a statistically significant reduction in lung cancer mortality among women (HR = 0.31 [95% CI: 0.10-0.96], p = 0.04), but not among men (HR = 0.94 [95% CI: 0.54-1.61], p = 0.81) screened by LDCT (pheterogeneity = 0.09). Findings from LUSI are in line with those from other trials, including NLST, that suggest a stronger reduction of lung cancer mortality after LDCT screening among women as compared to men. This heterogeneity could be the result of different relative counts of lung tumor subtypes occurring in men and women.
Item Description:Online 4 Jun 2019
Gesehen am 15.04.2020
Physical Description:Online Resource
ISSN:1097-0215
DOI:10.1002/ijc.32486

Similar Items